A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Eribulin (Primary) ; Gemcitabine (Primary) ; Ipatasertib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms PATHFINDER
- 04 Jun 2024 Results (At data cutoff (10th November 2023) assessing toxicity and efficacy of IPA with non-taxane CT in aTNBC pts presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2024 According to a MEDSIR media release, company today announced results from this clinical trial during the 2024 ASCO Annual Meeting.
- 05 Apr 2024 This study has been Completed in Portugal According to European Clinical Trials Database Record.